Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
NCT06040086
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD)
Birmingham, Alabama, United States
View Trial DetailsNCT Number: NCT02629432
The main objective of this trial is to prove that MRI - as the imaging modality without the use of ionizing radiation - can replace CT for structural and functional regional phenotyping of COPD. The identification of different COPD phenotypes, such as the "emphysema-type" and the "airway-type", is important because therapy and prognosis will be different. The medical problem addressed in this trial is the image-based phenotyping of COPD. The sensitivity and specificity of MRI will be compared to Lowdose-CT serving as the gold standard. MRI and CT of the lung will be performed in a multi-centre cohort of 625 COPD-patients from the main COSYCONET cohort. The reliability of the MRI results will be demonstrated. MRI phenotypes will be evaluated visually and using software with quantitative read-outs. The agreement of both will be determined. The additional information of MRI over CT will be assessed.
Looking for future studies?
Notify Me40 year and older
All sexes
Observational
Universitätsklinikum, Diagnostische und Interventionelle Radiologie und Neuroradiologie, Essen, Germany
This prospective trial aims to phenotype COPD by using Imaging methods.The identification of different COPD phenotypes, such as the "emphysema-type" and the "airway-type", is important because therapy and prognosis will be different. Imaging might play a central role in diagnosing these phenotypes. So far computed tomography (CT) is regarded as the gold standard, but it involves ionizing radiation and lacks functional information. The medical problem addressed in this trial is the image-based phenotyping of COPD. The principal research question is whether magnetic resonance imaging (MRI) can replace CT for the characterization of COPD by "structural and functional phenotyping" on a regional basis. The sensitivity and specificity of MRI will be compared to CT serving as the gold standard. To achieve this goal, MRI and CT of the lung will be performed in a multi-centre cohort of 625 COPD-patients from the main Cosyconet cohort. Also, the reliability of the MRI results will be demonstrated. MRI phenotypes will be evaluated visually and using software with quantitative read-outs. The agreement of both will be determined. The additional information of MRI over CT will be assessed. A special focus will be to implement an image-based biomarker of pulmonary functional reserve derived from the MRI measurement of pulmonary perfusion, which will be correlated with results from pulmonary functions tests (e.g. the lung transfer factor for carbon monoxide (TLCO)) the 6-minute walking test (6-MWD), and extrapulmonary disease manifestations.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Key inclusion criteria:
Exclusion criteria
Time frame: single time point/baseline only
diagnostic study, MRI and CT acquired on the same day
Time frame: single time point/baseline only
to assess the achievable image quality in a multicentre setting
Time frame: single time point/baseline only
to compare both modalities for the assessment of those parameters
Time frame: single time point/baseline only
to assess the value of MRI-based biomarkers in comparison to clinical data
Time frame: single time point/baseline only
to assess potential advantages of MR compared to CT
University Hospital Heidelberg
Other
Image-Based Structural and Functional Phenotyping of the COSYCONET Cohort Using MRI and CT (MR COPD)
Acronym: MR-COPD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06040086
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD)
Birmingham, Alabama, United States
View Trial DetailsNCT01917331
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD)
Szeged, Hungary
View Trial DetailsNCT06897748
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD)
Aramil, Russia
View Trial DetailsNCT04119934
Behavior, Chronic Disease
Toronto, Ontario, Canada
View Trial Details